NASDAQ:ERAS Erasca Q4 2024 Earnings Results & Report $14.73 +0.03 (+0.22%) As of 11:00 AM Eastern This is a fair market value price provided by Massive. Learn more. Erasca beat analyst earnings expectations in its Q4 2024 results, released March 20, 2025. The company reported EPS of -$0.11 versus the -$0.12 consensus estimate. Research:ProfileEarnings HistoryForecast Earnings Announcement Details QuarterQ4 2024Report DateMarch 20, 2025TimeBefore Market OpensConference Call12:00 AM ET Erasca EPS ResultsActual EPS-$0.11Consensus EPS -$0.12Beat/MissBeat by +$0.01One Year Ago EPS-$0.20EPS Beat Rate4 of last 8 quartersErasca Revenue ResultsActual RevenueN/AExpected RevenueN/ABeat/MissN/AYoY Revenue GrowthN/AUpcoming EarningsErasca's Q3 2026 earnings is estimated for Wednesday, November 11, 2026, based on past reporting schedules, with a conference call scheduled on Monday, November 9, 2026 at 4:00 PM ET. Check back for transcripts, audio, and key financial metrics as they become available.Conference Call ResourcesPress Release (8-K)Annual Report (10-K)Earnings HistoryCompany ProfilePowered by Earnings DocumentsPress Release(8-K)Annual report(10-K) Erasca Q4 2024 Earnings FAQ Did Erasca beat earnings estimates for Q4 2024? Erasca (NASDAQ:ERAS) reported earnings of -$0.11 per share for Q4 2024, beating the consensus estimate of -$0.12. The report was announced on Thursday, March 20, 2025. When is Erasca's next earnings date? Erasca's next earnings date is estimated for Wednesday, November 11, 2026. MarketBeat tracks confirmed and estimated earnings dates for Erasca on the company's earnings history page. Erasca Earnings HeadlinesErasca (NASDAQ:ERAS) Shares Down 5.1% - What's Next?October 5, 2026 | americanbankingnews.comErasca: Revolution's Approval Just Took Risk Out Of The Fast FollowerOctober 5, 2026 | seekingalpha.comALERT: Drop these 5 stocks before the market opens tomorrow!The Wall Street Journal is already raising the alarm about a potential market crash, and Weiss Ratings research points to the first half of 2026 as a particularly rough stretch for certain holdings. Some of America's most popular stocks could take serious damage as a radical market shift plays out. Analysts at Weiss Ratings have identified five names you may want to remove from your portfolio before this unfolds. If any of these are in your portfolio, now is the time to review your positions.October 15 at 1:00 AM | Weiss Ratings (Ad)ERASCA, INC. (NASDAQ: ERAS) SHAREHOLDER INVESTIGATION ALERT: Bernstein Liebhard Investigates Potential Breaches of Fiduciary DutySeptember 22, 2026 | globenewswire.comLong-Term Shareholders of Erasca, Inc. (ERAS) Are Encouraged to Contact Johnson Fistel Regarding Potential ClaimsSeptember 21, 2026 | globenewswire.comErasca’s ERAS-601 Trial Completion: What Early Cancer Data Could Mean for InvestorsSeptember 16, 2026 | tipranks.comSee More Erasca Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Erasca? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Erasca and other key companies, straight to your email. Email Address About ErascaErasca (NASDAQ:ERAS) is a clinical-stage biopharmaceutical company focused on developing precision medicines for cancers driven by abnormal signaling in the RAS/MAPK pathway. The company’s research and development activities target tumors with RAS mutations or other alterations that can promote cancer growth and resistance to treatment. Erasca’s pipeline has included naporafenib, an investigational pan-RAF inhibitor designed to block signaling downstream of RAF proteins, as well as other targeted therapies aimed at genetically defined cancer populations. Its programs are being evaluated in clinical studies, including potential treatments for solid tumors with limited therapeutic options. Founded in 2018 and headquartered in San Diego, California, Erasca became a publicly traded company on the Nasdaq under the symbol ERAS in 2021. The company is led by co-founder and Chief Executive Officer Jonathan E. Lim, M.D. Its operations are primarily focused on oncology research and clinical development in the United States, with collaborations and trial activities potentially extending to other regions.View Erasca ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles Citi Stock Falls Despite Earnings Beat: What Investors Need to KnowDon’t Get NVIDIA’s Reflection AI Interest Wrong: Its Moat Could DeepenBig Banks Report Strong Earnings—So Why Are Shares Falling?UnitedHealth Beats on Earnings, But Investors Question Growth PathIREN Limited's AI Pivot Gains Traction—But Can Its Data Centers Deliver?PBF Energy's Stunning Rally Faces a Critical TestA Chinese Rival Just Spooked Memory Stocks—How Worried Should Micron Investors Be? Upcoming Earnings Truist Financial (10/16/2026)Travelers Companies (10/16/2026)HDFC Bank (10/17/2026)ICICI Bank (10/17/2026)America Movil (10/20/2026)Netflix (10/20/2026)General Motors (10/20/2026)Chubb (10/20/2026)Capital One Financial (10/20/2026)Intuitive Surgical (10/20/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
